Business
Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil
Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the
About this update from Bavarian Nordic A/s
[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7d037B4FI93H1mEWMcPsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccine","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential to expand agreement to cover rest of Latin America","length":60,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":154,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America.","length":395,"tagName":"p"},{"type":"text","content":"The agreement is transfer price and royalty-based with no associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval of the vaccine in exclusive territories, as well as sales and distribution costs. Bavarian Nordic will remain the manufacturer of the vaccine, which is made available to Eurofarma through a transfer price agreement.","length":393,"tagName":"p"},{"type":"text","content":"Pending discussions with the Brazilian Health Regulatory Agency, Anvisa, regulatory submission is expected to occur later in the first half of 2026, potentially supporting launch of the chikungunya vaccine in Brazil in the second half of 2027.","length":243,"tagName":"p"},{"type":"text","content":"“Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to expand the commercial availability also for endemic populations through this first distribution agreement,” said Paul Chaplin, President &am...